Management of Combined Therapy (Ceritinib, A. cinnamomea , G. lucidum , and Photobiomodulation) in Advanced Non-Small-Cell Lung Cancer: A Case Report.
Chuan-Tsung SuJih-Huah WuPublished in: Life (Basel, Switzerland) (2022)
The 5-year survival rate of non-small-cell lung cancer (NSCLC) is still low (<21%) despite recent improvements. Since conventional therapies have a lot of side effects, combined therapy is strongly recommended. Here, we report a patient with advanced NSCLC who received combined therapy, including ceritinib, photobiomodulation (PBM), ACGL ( Antrodia cinnamomea ( A. cinnamomea ), and Ganoderma lucidum ( G. lucidum )). Based on combined therapy, suitable doses of A. cinnamomea , G. lucidum , and PBM are important for tumor inhibition. This case report presents clinical evidence on the efficacy of combined therapy in advanced NSCLC patients, including computed tomography (CT) scan, magnetic resonance imaging (MRI), carcinoembryonic antigen (CEA), and blood tests. The effective inhibition of human lung adenocarcinoma cells is demonstrated. Our case highlights important considerations for PBM and ACGL applications in NSCLC patients, the side effects of ceritinib, and long-term health maintenance.
Keyphrases
- advanced non small cell lung cancer
- computed tomography
- magnetic resonance imaging
- small cell lung cancer
- case report
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- healthcare
- public health
- endothelial cells
- peritoneal dialysis
- epidermal growth factor receptor
- stem cells
- cell proliferation
- patient reported outcomes
- induced apoptosis
- mesenchymal stem cells
- social media
- risk assessment
- cell cycle arrest
- tyrosine kinase
- patient reported